[
  {
    "ts": null,
    "headline": "AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin",
    "summary": "AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.",
    "url": "https://finnhub.io/api/news?id=33d170845893dfa1473ecb46b6263b20304be82d1d45de1645caf7124c59329c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760792736,
      "headline": "AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin",
      "id": 137160143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.",
      "url": "https://finnhub.io/api/news?id=33d170845893dfa1473ecb46b6263b20304be82d1d45de1645caf7124c59329c"
    }
  }
]